Our journey through Europe now takes us to Belgium – here are the highlights compiled by Hebias.

 

🏛️ 15 assessments published in April and May

🚫 No HTA procedures were published in June due to new legislation (Access Briefing in Q3 will include the information with impact per June 1, 2025)

➕️ Three Class 1 procedures (added value)

❌️ Five Class 2 procedures (no added value)

🧬 One Orphan drug procedure

⏰️ Five temporary conditional reimbursements

✅ One permanently listed products

 

🔄 Five Art 59MC procedures (rephrasing of the wording of the criteria per request of the CRM)

🔄 One Art 130 procedure (technical change without impact on price and population per request of the CRM)

 

📝 Register here to receive the latest and upcoming issues of the complete #AccessBriefing with HTA insights from 14 countries, compiled by 9 partners of our network 👉 https://forms.office.com/e/Jt8bPmVkdJ